These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
41 related articles for article (PubMed ID: 9441202)
1. Richard Klausner: NCI's multifaceted cancer fighter. Larkin M Lancet; 1997 Dec; 350(9093):1756. PubMed ID: 9441202 [No Abstract] [Full Text] [Related]
2. [Progress in the study of von Hippel-Lindau syndrome]. Chen F; Wu M Zhonghua Yi Xue Za Zhi; 1997 Mar; 77(3):236-8. PubMed ID: 9596966 [No Abstract] [Full Text] [Related]
3. The big three. NCI's Richard Klausner. Marshall E Science; 2001 Jun; 292(5524):1990. PubMed ID: 11408637 [No Abstract] [Full Text] [Related]
4. A PCR generated BsaJ I RFLP in the promoter of the von Hippel-Lindau disease (VHL) tumour suppressor gene. Geil L; Semenova E; Lerman MI; Kuzmin I Mol Cell Probes; 1998 Oct; 12(5):343-4. PubMed ID: 9778462 [No Abstract] [Full Text] [Related]
5. [VHL gene and TSC 2 gene]. Hino O Gan To Kagaku Ryoho; 1997 Sep; 24(11):1386-91. PubMed ID: 9309130 [TBL] [Abstract][Full Text] [Related]
15. The Klausner revolution. Marshall E Science; 1996 Sep; 273(5280):1328-9, 1331. PubMed ID: 8801625 [No Abstract] [Full Text] [Related]
16. Klausner follows own advice at NCI. Marshall E Science; 1995 Aug; 269(5226):912-3. PubMed ID: 7638609 [No Abstract] [Full Text] [Related]
17. National Cancer Institute. Klausner quits NCI to head new institute. Marshall E Science; 2001 Sep; 293(5537):1967. PubMed ID: 11557849 [No Abstract] [Full Text] [Related]
18. Collaboration to play key role in NCI's future, director says. Interview by Katherine Arnold. von Eschenbach A J Natl Cancer Inst; 2002 Jun; 94(11):790-2. PubMed ID: 12048262 [No Abstract] [Full Text] [Related]